The safety of ustekinumab in psoriasis
Famenini, S.; Wu, J.J.
Journal of Drugs in Dermatology Jdd 11(8): 907-910
2012
ISSN/ISBN: 1545-9616 PMID: 22859234 Document Number: 15598
Ustekinumab is effective in the treatment of a variety of autoimmune conditions including psoriasis. As a relatively new therapeutic agent, its long-term effects are still under investigation. Short-term studies, however, have revealed ustekinumab to be generally well tolerated and safe. This article provides a comprehensive review of the pharmacokinetics of ustekinumab, its safety profile, adverse effects, and use in pregnancy. The effect of diabetes and prior immunosuppressant therapy is also addressed.
Document emailed within 1 workday
Related Documents
Reich, K.; Papp, K.A.; Griffiths, C.E.M.; Szapary, P.O.; Yeilding, N.; Wasfi, Y.; Ott, E.; Hsu, M-Chun.; Lebwohl, M.; Gordon, K.B. 2012: An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up Journal of drugs in dermatology: JDD 11(3): 300-312Zhu, X.; Zheng, M.; Song, M.; Shen, Y.-K.; Chan, D.; Szapary, P.O.; Wang, B.; Wang, B.; Tu, C.; Hao, F.; Jin, H.; Xu, J.; Gu, J.; Zheng, M.; Gao, T.; Lai, W.; Liu, X.; Gao, X.; Zhu, X.; Zhang, J.; Zheng, J. 2013: Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS) Journal of Drugs in Dermatology: Jdd 12(2): 166-174
Famenini, S.; Wu, J.J. 2013: The efficacy of ustekinumab in psoriasis Journal of Drugs in Dermatology: Jdd 12(3): 317-320
Sandoval, L.F.; Huang, K.E.; Feldman, S.R. 2013: Adherence to ustekinumab in psoriasis patients Journal of Drugs in Dermatology: Jdd 12(10): 1090-1092
Andrulonis, R.; Ferris, L.K. 2012: Treatment of severe psoriasis with ustekinumab during pregnancy Journal of Drugs in Dermatology: Jdd 11(10): 1240
Talamonti, M.; Galluzzo, M.; Chiricozzi, A.; Teoli, M.; Bavetta, M.; Costanzo, A.; Chimenti, S. 2012: Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome Journal of Drugs in Dermatology: Jdd 11(8): 1000-1002
Opel, D.; Economidi, A.; Chan, D.; Wasfi, Y.; Mistry, S.; Vergou, T.; Antoniou, C.; Sofen, H. 2012: Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab Journal of Drugs in Dermatology: Jdd 11(12): 1498-1501
Zaghi, D.; Krueger, G.G.; Callis Duffin, K. 2012: Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis Journal of Drugs in Dermatology: Jdd 11(2): 160-167
Dickson, L.; Menter, A. 2017: Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab Journal of Drugs in Dermatology: Jdd 16(2): 177-179
Serirat, O. 2014: Observational cases report of a group of severe plaque type psoriasis patients treated with ustekinumab Journal of the Medical Association of Thailand 97 Suppl. 11: S150-S153
Brodmerkel, C.; Wadman, E.; Langley, R.G.; Papp, K.A.A.; Bourcier, M.; Poulin, Y.; Ho, V.; Guenther, L.; Kunynetz, R.; Nigen, S.; Vender, R.; Wasel, N.; Hsu, M.-C.; Szapary, P. 2013: Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use Journal of Drugs in Dermatology: Jdd 12(10): 1122-1129
Jensen, J.Daniel.; Huynh, T.; Cafardi, J.; Sami, N. 2013: Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series Journal of drugs in dermatology: JDD 12(6): 710-711
Tsai, T.-F.; Song, M.; Shen, Y.-K.; Schenkel, B.; Choe, Y.-B.; Kim, N.-I.; Lee, J.-H.; Lee, J.-H.; Song, H.-J.; Youn, J.-I. 2012: Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial Journal of Drugs in Dermatology: Jdd 11(8): 943-949
Krathen, R.A.; Berthelot, C.N.; Hsu, S. 2006: Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients Journal of Drugs in Dermatology: Jdd 5(3): 251-254
González-Chavez, J.é R.; Berlingeri-Ramos, A.C.; Sánchez Casiano, M.A. 2005: Puerto Rico psoriasis study group: efficacy and safety of etanercept Journal of Drugs in Dermatology: Jdd 4(6): 735-739
Kircik, L.H. 2017: Psoriasis Is a Chronic Disease: Long Term Efficacy and Safety of new Biologics Is Important Journal of Drugs in Dermatology: Jdd 16(8): S113-S114
Tanghetti, E.; Lebwohl, M.; Stein Gold, L. 2018: Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and its Emerging Role in Treatment Strategy Journal of Drugs in Dermatology: Jdd 17(12): 1280-1287
Jarratt, M.T.; Clark, S.D.; Savin, R.C.; Swinyer, L.J.; Safley, C.F.; Brodell, R.T.; Yu, K. 2006: Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis Cutis 78(5): 348-354
Polachek, A.; Korobko, U.; Mader-Balakirski, N.; Arad, U.; Levartovsky, D.; Kaufman, I.; Anouk, M.; Litinsky, I.; Wigler, I.; Mendelson, E.; Paran, D.; Matz, H.; Caspi, D.; Mandelboim, M.; Elkayam, O. 2015: Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis Clinical and Experimental Rheumatology 33(2): 181-186
Miyachi, Y.; Ohkawara, A.; Ohkido, M.; Harada, S.; Tamaki, K.; Nakagawa, H.; Hori, Y.; Nishiyama, S. 2002: Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris European Journal of Dermatology: Ejd 12(5): 463-468